Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

Despite the advances in intensive chemotherapy regimens and targeted therapies, overall survival (OS) of acute myeloid leukemia (AML) remains unfavorable due to inevitable chemotherapy resistance and high relapse rate, which mainly caused by the persistence existence of leukemia stem cells (LSCs). Bone marrow microenvironment (BMM), the home of hematopoiesis, has been considered to play a crucial role in both hematopoiesis and leukemogenesis. When interrupted by the AML cells, a malignant BMM formed and thus provided a refuge for LSCs and protecting them from the cytotoxic effects of chemotherapy. In this review, we summarized the alterations in the bidirectional interplay between hematopoietic cells and BMM in the normal/AML hematopoietic environment, and pointed out the key role of these alterations in pathogenesis and chemotherapy resistance of AML. Finally, we focused on the current potential BMM-targeted strategies together with future prospects and challenges. Accordingly, while further research is necessary to elucidate the underlying mechanisms behind LSC-BMM interaction, targeting the interaction is perceived as a potential therapeutic strategy to eradicate LSCs and ultimately improve the outcome of AML.

Automated summary

Despite advances in chemotherapy and targeted therapies, AML's survival rates are still poor due to chemotherapy resistance and high relapse rates caused by leukemia stem cells. The interaction between hematopoietic cells and the bone marrow microenvironment plays a key role in AML pathogenesis and chemotherapy resistance. Targeting this interaction could be a potential therapeutic strategy to eradicate LSCs and improve AML outcomes.